FDA panel in favor of Avandia

A Food and Drug Administration (FDA) advisory panel voted that Avandia, a GlaxoSmithKline diabetes drug, should remain on the market, following two days of discussion about the possibility of increased risk of heart attacks.

A Food and Drug Administration (FDA) advisory panel voted that Avandia, a GlaxoSmithKline diabetes drug, should remain on the market, following two days of discussion about the possibility of increased risk of heart attacks.

The FDA, which can choose whether to follow the recommendations of the panel, will make a final decision at a later date. GSK posted a statement to its website, saying it believes the drug is a safe and effective treatment for type 2 diabetes.

An analyst told the Los Angeles Times the vote is "positive" for the pharmaceutical company, but said he expects fewer physicians to use Avandia, which was once GSK's second-biggest drug, going forward.

GSK turned to its blog in February to address concerns about a report issued by the US Senate Finance Committee. Reports questioning the drug's safety first appeared in 2007.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.